Site-directed RNA editing
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 16, 2017
Grant Date -
N/A
app pub date -
Jul 20, 2013
filing date -
Jul 19, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The invention provides a way to target RNA editing by adenosine deamination to a chosen adenosine within RNA. An antisense RNA oligonucleotide is used for targeting the entire complex to a specific address on the RNA molecule. A Box B RNA and a λ N-peptide are used as a linkage between the antisense RNA oligonucleotide and a deaminase domain of human ADAR2 used to catalyze the deamination of the specific adenosine residue. These elements make up two molecules: the antisense RNA Oligo Box B RNA hairpin forms a single unit, as does the λ N-peptide-deaminase domain of human ADAR2.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully